Core Viewpoint - The digital subtraction angiography (DSA) system market is projected to reach $7.974 billion by 2031, with a compound annual growth rate (CAGR) of 7.18% in the coming years [1][4]. Market Overview - Major manufacturers of DSA systems globally include Philips, Siemens Healthineers, and Canon, with the top five companies holding approximately 92.90% of the market share [4]. - The primary product type is the floor-mounted C-arm system, which accounts for about 51.50% of the market [5]. - Cardiovascular diseases represent the largest demand source, capturing around 67.60% of the market [10]. Key Drivers - Aging Population and Disease Burden: The acceleration of aging in China and the rising incidence of cardiovascular diseases are driving the demand for DSA in interventional surgeries [14]. - Policy Support: The Chinese government is encouraging domestic production of high-end medical equipment through policies like the "Healthy China 2030" plan, which includes funding and tax incentives [14]. - Technological Integration and Upgrades: The integration of AI and 3D reconstruction technologies is enhancing diagnostic efficiency and promoting the development of DSA towards precision and minimally invasive procedures [14]. Challenges - Dependence on Core Components: High-end DSA equipment relies on advanced components, and while domestic companies have made progress, they still lag behind international giants in key technologies [16]. - Patent Barriers: Domestic companies face potential patent infringement issues during R&D, which can hinder innovation [16]. - Service and Maintenance Costs: High maintenance costs and insufficient service network coverage for domestic companies compared to international brands pose challenges [17]. Industry Opportunities - Government Initiatives: The National Health Commission's guidance on promoting domestic high-end medical equipment development is expected to support local companies [18]. - Market Expansion in Rural Areas: The "Thousand County Project" aims for 90% of county-level hospitals to be equipped with DSA devices by 2027, with financial support covering 30%-40% of procurement costs [18]. - Regulatory Support for Innovation: The introduction of expedited approval processes for DSA devices with integrated AI functionalities is likely to enhance market entry for innovative products [18].
全球数字减影血管造影系统市场前10强生产商排名及市场占有率
QYResearch·2025-09-01 09:42